An interventional study of Programmed intermittent epidural bolus 5 ml and Programmed intermittent epidural bolus 6 ml in Acute Post Operative Pain, Laparotomy and Epidural Analgesia, sponsored by Ciusss de L'Est de l'Île de Montréal. Completed at 1 site in Canada. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Ciusss de L'Est de l'Île de Montréal · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 190 studies in Pain, Postoperative with a site in Canada — 38 open to participants now, 42 under way, 3 of them phase 3. Pain, Postoperative · Canada.
Among the 190 studies in Pain, Postoperative with a site in Canada, this one is the 109th largest by enrollment of the 175 interventional ones that give a count, is one of 13 that started in 2022, is one of 94 with no phase, and was the 146th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →38 of the 190 studies in Pain, Postoperative with a site in Canada are open now. Recruiting first, the newest first:
Université de Sherbrooke · Sites in Canada
Ages 18+
Mount Sinai Hospital, Canada · Sites in Canada
Ages 18+ · Women only · Healthy volunteers
Mount Sinai Hospital, Canada · Sites in Canada
Ages 18+ · Women only · Healthy volunteers
Université de Sherbrooke · Sites in Canada
Ages 18+
University of Calgary · Sites in Canada
Ages 18+ · Women only · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
190 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 17 · Phase 3 22 · Phase 4 38
First in 2004; this study’s year is marked. 13 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 82 across the 175 interventional studies, 140 across the 15 observational. Of the 125 that completed or were terminated, 8 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 190 have an industry lead sponsor. The 10 most frequent:
Ciusss de L'Est de l'Île de Montréal is the lead sponsor of 90 studies on the registry; 32 are open to participants now.
Ciusss de L'Est de l'Île de Montréal has 7 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
13 of the studies in Pain, Postoperative with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07434310Phase 3Dr. Naveed SiddiquiUse of Dexmedetomidine to Improve Pain Control and Recovery After Laparocopic-Assisted Bowel Surgery in Adults | 2027-07-01 |
| NCT06324942University of CalgaryAnalgesic Efficacy of Surgeon-administered Transversus Abdominis Plane Blocks for Caesarean Section. | 2026-12 |
| NCT06276257CHU de Quebec-Universite LavalParavertebral Block for Mastectomy With Immediate Reconstruction | 2026-12 |
| NCT03675386University Health Network, TorontoReducing Opioid Use for Chronic Pain Patients Following Surgery | 2026-12-31 |
| NCT05722002University of MichiganComparing Analgesic Regimen Effectiveness and Safety for Surgery (CARES) Trial | 2027-02-10 |
Add all 13 to your calendar (.ics) → With an account.
Among the 190 studies in Pain, Postoperative with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pain control after surgery is a crucial component of postoperative recovery. Thus, in open abdominal surgery, the use of TEA (Thoracic epidural analgesia) has become a gold standard. However, analgesia may still remain a challenge, especially in patients with large incision abdominal incisions.
To address this problem, the use of the PIEB (Programmed intermittent epidural bolus) mode has been proposed, because it offers a better spread of the epidural medication.
Only a few studies have evaluated the superiority of this PIEB mode in open abdominal surgery, yielding conflicting results. However, PIEB showed to be at least as effective in controlling pain as CEI, and clinical experience shows that it can be a valuable tool, especially in patients with a large laparotomy incision.
However, the optimal dosage of the PIEB mode has never been determined, Furthermore, it is known whether men and women have the same dosage needs to achieve adequate analgesia since most studies have failed to account for sex-based differences in postoperative analgesia.
Hence, the main objective of this study will be to determine the optimal volume dose of the PIEB delivered at a fixed interval of 60 min in patients undergoing surgery using a large midline laparotomy incision. The optimal dose for male and female patients will be determined separately by evaluating men and women in two independent groups. We hypothesize that the optimal dose of the PIEB that will provide effective analgesia in 90% of patients on the first postoperative day will range between 5 and 10 mL, for both groups.
The primary outcome in both groups is successful analgesia. It is defined as a requirement of 5 or less patient-controlled epidural boluses between 8 AM and 8 PM on the first postoperative day.
Secondary outcomes will be the incidence of motor block and hypotension, comparison of the level of sensory block according to group, comparison of patient satisfaction according to group and comparison of Quality of Recovery-15 score at 48h post-op according to group.
Objective : To identify the optimal volume dosage of epidural bupivacaine administered with a PIEB protocol using a biased coin up-down sequential allocation method. This optimal dose will be determined separately for men and women to account for possible sex-based differences in postoperative analgesia.Only patients undergoing surgery requiring a large laparotomy incision will be included.
Hypothesis : the optimal dose of the PIEB that will provide effective analgesia in 90% of patients on the first postoperative day using an epidural solution of 0,05% bupivacaine + fentanyl 2 µg/mL + adrenaline 2 µg/mL will range between 5 and 10 mL in both groups.
Population : Patients undergoing elective open abdominal surgery via a midline incision extending above and below the umbilicus (>25 cm) with planned TEA.
Screening and recruitment : Eligible patients undergoing gastro-intestinal, gynecological and vascular procedures will be screened by looking at the operating room schedule 2-3 days prior to surgery. The patient files will be checked for inclusion and exclusion criteria, and eligible patients will be contacted preoperatively by phone to further verify eligibility and to inform them of the research project. Written informed consent will be obtained by the research nurse on the morning of surgery. Patients of female sex will be allocated to the female group and patients of male sex will be allocated to the male group. Patients will be instructed preoperatively about the pain scale (11-points pain scale of 0-10, where 0: no pain at all and 10: worst imaginable pain) and about how to use the PCEA pump.
Anesthesia management : Upon arriving in the operating room and after installing a peripheral intravenous access and standard ASA monitoring, patient will be pe-medicated with midazolam 0,5-1 mg IV and/or sufentanil 5-10 mcg IV or fentanyl 50-100 mcg IV. Thoracic epidural catheter will be installed in the sitting position using a loss of resistance technique in the low thoracic spine (preferably T11-T12, or T10-T11 alternatively). To ensure consistency in lumbar level of puncture, spinal ultrasound will be used in all cases. The last and second to last thoracic ribs will be identified and followed medially until the laminas and the T11-T12 and T10-T11 interspaces, respectively, which will then be marked using a skin marker. After skin disinfection and local anesthesia, the epidural space will be identified using a loss of resistance to saline technique and the catheter will be inserted 3-5 cm into the epidural space. Correct placement will be verified with negative aspiration of the catheter and a negative test dose using 3 ml of lidocaine 2% + epinephrine 1:200 000.
Anesthesia induction will be performed using: Lidocaine 0.4-1 mg/kg, Sufentanil 0,1-0,2 mcg/kg or Fentanyl 1-2 mcg/kg and/or remifentanil 0.25-1 mcg/kg, Propofol 1-3 mg/kg and Rocuronium 0,6-1,2 mg/kg. Endotracheal intubation will be achieved using a videolaryngoscope.
General anesthesia will be maintained with sevoflurane to target a Bispectral index (BIS) between 40-60. Intraoperative analgesia will be guided by the Nociception Level Index (NOL). An epidural infusion of bupivacaine 0.125% 1-3 mL/h, with or without epidural boluses of 1-5 mL every 30-60 min and/or opioids (remifentanil, fentanyl and/or sufentanil) can be used at the discretion of the anesthesiologist, to maintain a NOL index \< 25. This will facilitate protocol adherence and minimize the risk of hemodynamic instability. Intraoperative fluid administration will consist of a basal infusion of Lactated Ringer set at 3 mL/kg/h, and additional cristalloids/colloids boluses will be administered to cover for blood losses and with the goal of maintaining a pulse pressure variation \< 12%. The use of intravenous lidocaine, dexmedetomidine, or ketamine is not allowed.
All patients will receive double anti-emetic prophylaxis consisting of dexamethasone 4 mg and ondansetron 4 mg.
At the beginning of skin closure, a 5 ml mandatory epidural bolus of bupivacaine 0,125% will be administered and any intraoperative infusion will be stopped. The time at which this bolus is administered will be noted.
PACU : After extubation, patients will be brought to the PACU. When patients are oriented, cold sensibility testing will be performed bilaterally at the level of the surgical incision to ensure adequate coverage. Inadequate/absent block will be treated with 1 or 2 epidural boluses of 5 mL of bupivacaine 0.125% every 15 min, as needed. The temperature test will be repeated 15 minutes after the last bolus. If the sensory coverage is still insufficient, patients will be excluded from the study. The epidural catheter will be connected to the infusion pump and the epidural infusion will be started according to study group, with the first bolus occurring 30 minutes after the last bolus.
TEA medication and management :
Data collection : Data collection will be conducted by a research team member, who will be blinded to the patient's group.
Pre-op :
Per-op :
Post-op :
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Female patients in this group will receive a 5 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
Drug: Programmed intermittent epidural bolus 5 ml
Female patients in this group will receive a 6 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
Drug: Programmed intermittent epidural bolus 6 ml
Female patients in this group will receive a 7 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
Drug: Programmed intermittent epidural bolus 7 ml
Female patients in this group will receive a 8 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
Drug: Programmed intermittent epidural bolus 8 ml
Female patients in this group will receive a 9 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
Drug: Programmed intermittent epidural bolus 9 ml
Female patients in this group will receive a 10 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
Drug: Programmed intermittent epidural bolus 10 ml
Male patients in this group will receive a 5 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
Drug: Programmed intermittent epidural bolus 5 ml
Male patients in this group will receive a 6 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
Drug: Programmed intermittent epidural bolus 6 ml
Male patients in this group will receive a 7 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
Drug: Programmed intermittent epidural bolus 7 ml
Male patients in this group will receive a 8 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
Drug: Programmed intermittent epidural bolus 8 ml
Male patients in this group will receive a 9 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
Drug: Programmed intermittent epidural bolus 9 ml
Male patients in this group will receive a 10 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
Drug: Programmed intermittent epidural bolus 10 ml
patients in this group will receive a programmed epidural intermittent bolus of 5 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
Also known as: 5 mL
patients in this group will receive a programmed epidural intermittent bolus of 6 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
Also known as: 6 mL
patients in this group will receive a programmed epidural intermittent bolus of 7 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
Also known as: 7 mL
patients in this group will receive a programmed epidural intermittent bolus of 8 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
Also known as: 8 mL
patients in this group will receive a programmed epidural intermittent bolus of 9 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
Also known as: 9 mL
patients in this group will receive a programmed epidural intermittent bolus of 10 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
Also known as: 10 mL
Successful analgesia
Defined by a requirement of a maximum of 5 Patient controlled epidural analgesia (PCEA) boluses on postoperative day 1
Time frame: from 8 AM until 8 PM on the first postoperative day
Incidence of motor block according to group
Incidence of Bromage Scale score of at least 3 (bromage motor blockade score from 1-4 where 1: complete motor blockade and 4: absence of motor block)
Time frame: At 24h postoperatively
Incidence of hypotension according to group
Systolic blood pressure \< 90 mmHg
Time frame: At 24h postoperatively
level of sensory block to ice according to group
Comparison of the level of sensory block to ice according to group (measured using loss of sensation to cold using an ice cube)
Time frame: At 24h postoperatively
Quality of Recovery-15 (QoR-15) score
Comparison of Quality of Recovery-15 (QoR-15) score according to group (scale of 0-150 where 0: very poor recovery and 150: best possible recovery)
Time frame: At 48 h postoperatively
Pain score at rest-24h
Intensity of pain at rest at 24h postoperatively using a verbal numeric pain score (0-10: 0 : no pain, 10: worst imaginable pain)
Time frame: at 24h postoperatively
Pain score with movement-24h
Intensity of pain with movement at 24h postoperatively using a verbal numeric pain score (0-10: 0 : no pain, 10: worst imaginable pain)
Time frame: at 24h postoperatively
Plan to share: No — We do not plan on sharing any personale information
No publications or documents are linked to this record.
Ran from Dec 2022 to primary completion in Sep 2026, 45 months.
Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 45 months is above that.
Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Jul 2026 → Sep 2026 and completion Dec 2026 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ciusss de L'Est de l'Île de Montréal